C2N Diagnostics to Open New St. Louis Facility in 2027
The Alzheimer's testing company will expand into a new space at the Catalyst building to triple its operational footprint.
Updated on Oct. 21, 2026 in Alzheimer’s
Live Poll
Do specialized innovation districts successfully keep growing companies within your local community?
C2N Diagnostics plans to relocate its St. Louis operations into a new 82,451-square-foot facility at the Catalyst building in the Cortex Innovation District. The company expects to begin scaling up its clinical testing at the site by 2027.
Why it matters
The expansion will provide the company with three to four times the clinical laboratory space currently available, allowing it to meet the growing demand for Alzheimer's diagnostic testing. The move highlights the role of the St. Louis region in supporting specialized medical infrastructure and research.
The new facility at 4140 Forest Park Avenue will span three floors and 82,451 square feet. This expansion will provide three to four times the clinical laboratory space currently in use by the company.
The players
C2N Diagnostics
A healthcare company that specializes in clinical testing and the development of diagnostic tools for Alzheimer's disease.
WashU
A prominent research university in St. Louis that manages regional development projects like the Catalyst building.
The details
C2N Diagnostics uses liquid chromatography-tandem mass spectrometry to measure biological markers for Alzheimer's disease. The company is collaborating with architects and engineers to design specialized laboratories within the Catalyst building, which was redeveloped by WashU from a former Goodwill Industries property.
Timeline
September 2025: C2N Diagnostics announced plans to move into the Catalyst building.
2027: C2N expects to begin scaling up clinical testing at the new facility.
The Big Picture
This development follows the pattern of medical firms centralizing operations within the Cortex Innovation District to leverage the regional research ecosystem. It reinforces the role of such districts in attracting specialized diagnostic companies to the city.
This expansion increases the capacity for the company to perform clinical testing for Alzheimer's disease. Increased diagnostic throughput may improve access for patients needing biomarker analysis as part of their clinical evaluation.
The takeaway
The move demonstrates how companies scale their infrastructure to match the increasing demand for neurodegenerative diagnostic services. As diagnostic technology advances, companies rely on custom laboratory design to integrate complex mass spectrometry equipment effectively.
Further reading
Learn more about the latest developments in Alzheimer’s.
Source note: This article includes information reported by St. Louis Magazine.
Live Poll
Do specialized innovation districts successfully keep growing companies within your local community?
